Related Experiment Video
Updated: Jun 17, 2025
08:56
Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells
Published on: July 12, 2022
2.9K
Therapy-Induced Cellular Senescence: Potentiating Tumor Elimination or Driving Cancer Resistance and Recurrence?
Yue Liu1, Isabelle Lomeli1, Stephen J Kron1
1Ludwig Center for Metastasis Research and Department of Molecular Genetics and Cell Biology, The University of Chicago, Chicago, IL 60637, USA.
Cells
|August 9, 2024
Summary
Cellular senescence, a state linked to aging and cancer, has a dual role in therapy. Senescent cells (SnCs) can promote or hinder cancer treatment, influencing tumor immunity and treatment response.
Area of Science:
- Oncology
- Cell Biology
- Immunology
Background:
- Cellular senescence is a key factor in cancer development and aging.
- Therapy-induced senescence (TIS) is a complex response to cancer treatments.
- Senescent cells (SnCs) exhibit a dual role in cancer, potentially promoting resistance or enhancing therapy outcomes.
Purpose of the Study:
- To review the multifaceted role of SnCs in cancer therapy.
- To explore the influence of the senescence-associated secretory phenotype (SASP) on the tumor microenvironment.
- To discuss strategies for leveraging TIS to improve cancer immunotherapy.
Main Methods:
- Literature review of cellular senescence in cancer.
- Analysis of the senescence-associated secretory phenotype (SASP) and its mechanisms.
- Exploration of TIS in relation to tumor immunity and treatment response.
Main Results:
- SnCs, via SASP, can mediate both resistance and response to cancer therapies.
- TIS has the potential to enhance anti-tumor immunity and potentiate immune checkpoint blockade.
- Persistent SnCs can negatively impact normal tissues and contribute to recurrence.
Conclusions:
- Senescence presents a "Jekyll and Hyde" nature in cancer treatment, requiring careful consideration.
- Targeting SnCs or modulating SASP offers novel therapeutic strategies.
- Harnessing TIS may improve the efficacy of cancer immunotherapy and reduce treatment side effects.
Related Concept Videos
02:15Replicative Cell Senescence
3.6K
Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds...
3.6K
02:53Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
02:40Cancer Stem Cells and Tumor Maintenance
4.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:27Tumor Immunotherapy
497
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
497